Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
Lenvatinib is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), but the effect of dose modification on its efficacy is unclear. We analyzed the relationship between the relative dose intensity during the initial 4 weeks of therapy [4W-relative dose intensity (RDI)] and...
Main Authors: | Sakura Kirino, Kaoru Tsuchiya, Masayuki Kurosaki, Shun Kaneko, Kento Inada, Koji Yamashita, Leona Osawa, Yuka Hayakawa, Shuhei Sekiguchi, Mao Okada, Wan Wang, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Nobuharu Tamaki, Yutaka Yasui, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Namiki Izumi |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0231828 |
Similar Items
-
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
by: Wan Wang, et al.
Published: (2019-10-01) -
Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis
by: Kento Inada, et al.
Published: (2021-09-01) -
<i>Wisteria floribunda</i> Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup
by: Nobuharu Tamaki, et al.
Published: (2021-12-01) -
Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
by: Hitomi Takada, et al.
Published: (2019-08-01) -
Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
by: Nobuharu Tamaki, et al.
Published: (2020-06-01)